1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed) is sponsored by NIH.
This funding opportunity supports research project grant (R01) applications for discrete, specified, circumscribed projects (up to 5 years) to be performed by named investigator(s) in an area representing the investigator's specific interest and competencies, focusing on immunometabolic responses to HIV infection that increase TB or HBV risk. Preliminary data is required.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Named investigator(s) at eligible institutions with preliminary data to support hypotheses and/or justify descriptive studies. Confirm the full requirements in the official notice before applying.
Applications for Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed) are due January 8, 2028. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed) is funded by NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
On November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read articleR&D World's count of NIH RePORTER data shows 13,686 new awards in FY2026, up 21% from 11,272 in FY2025, while total extramural grants fell to about 56,600. New R01s hit 4,960. What the split means for FY2027 applicants.
Read articleRFA-EB-28-004, NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18), puts about $6 million into 8 to 12 BRAIN and HEAL Initiative device-development awards. Budgets should rarely exceed $750,000 in direct costs a year, projects run up to three years, nine institutes participate, and there are six due dates from February 1, 2027 through February 1, 2030. Here is what the program requires and how to write a competitive application.
Read article